Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • June 29th, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
THIS SPONSORED RESEARCH AGREEMENT (together with the attached Exhibits, the “Agreement”), dated as of July 27, 2009 (the “Effective Date”), is by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation with a principal office at 300 Third Street, Cambridge, MA 02142, USA (“Alnylam”), The University of British Columbia, a corporation continued under the University Act of British Columbia, Canada, with offices at 103-6190 Agronomy Road, Vancouver, British Columbia, Canada (“UBC”) and AlCana Technologies, Inc., a British Columbia corporation with a principal business address at 2714 West 31st Avenue, Vancouver, British Columbia, Canada V6L 2A1 (“AlCana”). Each of Alnylam, UBC and AlCana may be referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Alnylam — Tekmira — Protiva — UBC — AlCana Supplemental Agreement Effective July 27, 2009Supplemental Agreement • June 29th, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
This Supplemental Agreement is made by and among Alnylam Pharmaceuticals, Inc. (“Alnylam”), Tekmira Pharmaceuticals Corporation (“Tekmira”), Protiva Biotherapeutics Inc., a wholly-owned subsidiary of Tekmira (“Protiva”), the University of British Columbia (“UBC”), and AlCana Technologies, Inc. (“AlCana”), as of the effective date stated above.
